Narjes Nasiri-Ansari
Overview
Explore the profile of Narjes Nasiri-Ansari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
510
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zachou M, Flevari P, Nasiri-Ansari N, Varytimiadis C, Kalaitzakis E, Kassi E, et al.
Eur J Clin Pharmacol
. 2023 Nov;
80(1):127-150.
PMID: 37938366
Purpose: Non-alcoholic fatty liver disease (NAFLD) has become a leading cause of liver disease, affecting 30% of the global population. NAFLD prevalence is particularly high in obese individuals and patients...
2.
Tsave O, Iordanidou C, Hatzidimitriou A, Yavropoulou M, Kassi E, Nasiri-Ansari N, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511624
The prospect of developing soluble and bioavailable Ti(IV) complex forms with physiological substrates, capable of influencing (patho)physiological aberrations, emerges as a challenge in the case of metabolism-related pathologies (e.g., diabetes...
3.
Karapanagioti A, Nasiri-Ansari N, Moustogiannis A, Trigas G, Zografos G, Aggeli C, et al.
Endocrine
. 2023 May;
81(2):357-367.
PMID: 37221428
Purpose: CHCHD2 is an antiapoptotic mitochondrial protein acting through the BCL2/BAX pathway in various cancers. However, data on the regulatory role of CHCHD2 in adrenal tumourigenesis are scarce. Methods: We...
4.
Dalamaga M, Nasiri-Ansari N, Spyrou N
Cancers (Basel)
. 2023 Mar;
15(6).
PMID: 36980657
The emergence of COVID-19 has created an unprecedented threat worldwide, involving overwhelmed health-care systems in the majority of countries [...].
5.
6.
Flessa C, Nasiri-Ansari N, Kyrou I, Leca B, Lianou M, Chatzigeorgiou A, et al.
Int J Mol Sci
. 2022 Dec;
23(24).
PMID: 36555433
A rapidly increasing incidence of non-alcoholic fatty liver disease (NAFLD) is noted worldwide due to the adoption of western-type lifestyles and eating habits. This makes the understanding of the molecular...
7.
Nasiri-Ansari N, Spilioti E, Kyrou I, Kalotychou V, Chatzigeorgiou A, Sanoudou D, et al.
Int J Mol Sci
. 2022 Sep;
23(18).
PMID: 36142876
In the presence of established atherosclerosis, estrogens are potentially harmful. MMP-2 and MMP-9, their inhibitors (TIMP-2 and TIMP-1), RANK, RANKL, OPG, MCP-1, lysyl oxidase (LOX), PDGF-β, and ADAMTS-4 play critical...
8.
Valatsou A, Theofilis P, Simantiris S, Vogiatzi G, Briasoulis A, Sagris M, et al.
Biomedicines
. 2022 Sep;
10(9).
PMID: 36140404
Novel therapies in peripheral arterial disease, such as granulocyte colony-stimulating factor (GCSF) administration, might result in anti-atherosclerotic effects. In this study, we used 10-week-old male ApoE mice, which were fed...
9.
Nasiri-Ansari N, Androutsakos T, Flessa C, Kyrou I, Siasos G, Randeva H, et al.
Cells
. 2022 Aug;
11(16).
PMID: 36010588
Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide. It is strongly associated with obesity, type 2 diabetes (T2DM), and other metabolic syndrome features. Reflecting...
10.
Tsilingiris D, Nasiri-Ansari N, Spyrou N, Magkos F, Dalamaga M
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626099
The COVID-19 pandemic brought about an unprecedented societal and healthcare system crisis, considerably affecting healthcare workers and patients, particularly those with chronic diseases. Patients with hematologic malignancies faced a variety...